HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $3 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on X4 Pharmaceuticals (NASDAQ:XFOR) and maintained a price target of $3.
August 11, 2023 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
X4 Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $3.
The reiterated 'Buy' rating from HC Wainwright & Co. indicates a positive outlook for X4 Pharmaceuticals. This could potentially attract more investors, driving up the stock price in the short term. The maintained price target of $3 also suggests that the analyst believes the stock is currently undervalued, which could further boost investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100